Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.

NCT06726265 is registered in ClinicalTrials.gov with Immutep S.A.S. as lead sponsor.

NCT NCT06726265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06726265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.
Lead sponsor
Immutep S.A.S.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 21, 2025
Completion date
September 30, 2029
Enrollment
756 (estimated)
Sites
147

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic non-small cell lung cancer (nsclc)